Nexell becomes free-standing company with Baxter support
This article was originally published in Clinica
Nexell Therapeutics is set to become a free-standing cell therapy company as Baxter, which owns a minority share in Nexell, transfers sales and marketing rights back to Nexell, as well as committing financial support. At the same time, Nexell's parent company will fold itself into its subsidiary and adopt its name and corporate headquarters.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.